256 related articles for article (PubMed ID: 32436733)
1. Quality of life of women using the etonogestrel long-acting reversible contraceptive implant after abortion for unplanned pregnancy.
Caruso S; Vitale SG; Fava V; Pasqua SD; Rapisarda AMC; Cianci S
Eur J Contracept Reprod Health Care; 2020 Aug; 25(4):251-258. PubMed ID: 32436733
[TBL] [Abstract][Full Text] [Related]
2. Immediate versus delayed insertion of an etonogestrel releasing implant at medical abortion-a randomized controlled equivalence trial.
Hognert H; Kopp Kallner H; Cameron S; Nyrelli C; Jawad I; Heller R; Aronsson A; Lindh I; Benson L; Gemzell-Danielsson K
Hum Reprod; 2016 Nov; 31(11):2484-2490. PubMed ID: 27664217
[TBL] [Abstract][Full Text] [Related]
3. Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion.
Steinauer JE; Upadhyay UD; Sokoloff A; Harper CC; Diedrich JT; Drey EA
Contraception; 2015 Dec; 92(6):553-9. PubMed ID: 26093190
[TBL] [Abstract][Full Text] [Related]
4. Sexual function and quality of life of women adopting the levonorgestrel-releasing intrauterine system (LNG-IUS 13.5 mg) after abortion for unintended pregnancy.
Caruso S; Cianci S; Vitale SG; Fava V; Cutello S; Cianci A
Eur J Contracept Reprod Health Care; 2018 Feb; 23(1):24-31. PubMed ID: 29436865
[TBL] [Abstract][Full Text] [Related]
5. Intra-abortion contraception with etonogestrel subdermal implant.
Barros Pereira I; Carvalho RM; Graça LM
Eur J Obstet Gynecol Reprod Biol; 2015 Feb; 185():33-5. PubMed ID: 25522115
[TBL] [Abstract][Full Text] [Related]
6. Not seeking yet trying long-acting reversible contraception: a 24-month randomized trial on continuation, unintended pregnancy and satisfaction.
Hubacher D; Spector H; Monteith C; Chen PL
Contraception; 2018 Jun; 97(6):524-532. PubMed ID: 29470950
[TBL] [Abstract][Full Text] [Related]
7. Long-acting reversible contraceptive acceptability and unintended pregnancy among women presenting for short-acting methods: a randomized patient preference trial.
Hubacher D; Spector H; Monteith C; Chen PL; Hart C
Am J Obstet Gynecol; 2017 Feb; 216(2):101-109. PubMed ID: 27662799
[TBL] [Abstract][Full Text] [Related]
8. Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women.
Xu H; Wade JA; Peipert JF; Zhao Q; Madden T; Secura GM
Obstet Gynecol; 2012 Jul; 120(1):21-6. PubMed ID: 22678035
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and continuation rates of the etonogestrel-subdermal contraceptive implant versus short-acting contraceptive methods offered at no cost in Campinas, Brazil.
Laporte M; Marcelino AC; da Cunha Pereira P; Espejo-Arce X; Juliato CT; Bahamondes L
Int J Gynaecol Obstet; 2024 Jul; 166(1):305-311. PubMed ID: 38328989
[TBL] [Abstract][Full Text] [Related]
10. Postpartum contraception: initiation and effectiveness in a large universal healthcare system.
Brunson MR; Klein DA; Olsen CH; Weir LF; Roberts TA
Am J Obstet Gynecol; 2017 Jul; 217(1):55.e1-55.e9. PubMed ID: 28257962
[TBL] [Abstract][Full Text] [Related]
11. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration.
McNicholas C; Swor E; Wan L; Peipert JF
Am J Obstet Gynecol; 2017 Jun; 216(6):586.e1-586.e6. PubMed ID: 28147241
[TBL] [Abstract][Full Text] [Related]
12. Increasing uptake of long-acting reversible contraception with structured contraceptive counselling: cluster randomised controlled trial (the LOWE trial).
Emtell Iwarsson K; Envall N; Bizjak I; Bring J; Kopp Kallner H; Gemzell-Danielsson K
BJOG; 2021 Aug; 128(9):1546-1554. PubMed ID: 33988917
[TBL] [Abstract][Full Text] [Related]
13. Real-world cost-effectiveness of etonogestrel implants compared to long-term and short term reversible contraceptive methods in France.
Linet T; Lévy-Bachelot L; Farge G; Crespi S; Yang JZ; Robert J; Fabron C
Eur J Contracept Reprod Health Care; 2021 Aug; 26(4):303-311. PubMed ID: 33960248
[TBL] [Abstract][Full Text] [Related]
14. Impact of a pay-for-performance scheme for long-acting reversible contraceptive (LARC) advice on contraceptive uptake and abortion in British primary care: An interrupted time series study.
Ma R; Cecil E; Bottle A; French R; Saxena S
PLoS Med; 2020 Sep; 17(9):e1003333. PubMed ID: 32925909
[TBL] [Abstract][Full Text] [Related]
15. Long-acting reversible contraceptive use in the post-abortion period among women seeking abortion in mainland China: intentions and barriers.
Luo Z; Gao L; Anguzu R; Zhao J
Reprod Health; 2018 May; 15(1):85. PubMed ID: 29793501
[TBL] [Abstract][Full Text] [Related]
16. Risk factors and the choice of long-acting reversible contraception following medical abortion: effect on subsequent induced abortion and unwanted pregnancy.
Korjamo R; Heikinheimo O; Mentula M
Eur J Contracept Reprod Health Care; 2018 Apr; 23(2):89-96. PubMed ID: 29537321
[TBL] [Abstract][Full Text] [Related]
17. Impact of an implantable steroid contraceptive (etonogestrel-releasing implant) on quality of life and sexual function: a preliminary study.
Di Carlo C; Sansone A; De Rosa N; Gargano V; Tommaselli GA; Nappi C; Bifulco G
Gynecol Endocrinol; 2014 Jan; 30(1):53-6. PubMed ID: 24131079
[TBL] [Abstract][Full Text] [Related]
18. Immediate postabortion initiation of levonorgestrel implants reduces the incidence of births and abortions at 2 years and beyond.
Rose SB; Garrett SM; Stanley J
Contraception; 2015 Jul; 92(1):17-25. PubMed ID: 25818594
[TBL] [Abstract][Full Text] [Related]
19. Temporal Trends in the Uptake and Continuation of the Etonogestrel Implant in a Large Private Practice Setting.
Howard DL; Ford A; Ceballos S; Volker KW
J Womens Health (Larchmt); 2018 Feb; 27(2):191-195. PubMed ID: 28976797
[TBL] [Abstract][Full Text] [Related]
20. Relative cost effectiveness of Depo-Provera, Implanon, and Mirena in reversible long-term hormonal contraception in the UK.
Varney SJ; Guest JF
Pharmacoeconomics; 2004; 22(17):1141-51. PubMed ID: 15612832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
